Cargando…
Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
OBJECTIVE: To assess the role of social risk factors on adherence to tyrosine kinase inhibitors (TKI) therapy in chronic myeloid leukemia (CML) patients. METHODS: This is a retrospective study and eligible patients were adults with CML on TKI treatment. Cases of no adherence to treatment were confir...
Autores principales: | Okumura, Lucas M., Antunes, Valquíria D., Aguiar, Karina S., Farias, Tatiane, Andrzejevski, Vânia M., Funke, Vaneuza M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centro de Investigaciones y Publicaciones Farmaceuticas
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482844/ https://www.ncbi.nlm.nih.gov/pubmed/26131044 |
Ejemplares similares
-
Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009) -
Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: Indian perspective
por: Ghosh, K
Publicado: (2022) -
Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022) -
The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor–Treated Chronic Myelogenous Leukemia
por: Lavoie, Declan C T, et al.
Publicado: (2019) -
Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
por: Kaehler, Meike, et al.
Publicado: (2021)